Immutep Future Growth
Future criteria checks 2/6
Immutep is forecast to grow earnings and revenue by 24.8% and 71.2% per annum respectively. EPS is expected to grow by 69.5% per annum. Return on equity is forecast to be -68.8% in 3 years.
Key information
24.8%
Earnings growth rate
69.5%
EPS growth rate
Biotechs earnings growth | 31.0% |
Revenue growth rate | 71.2% |
Future return on equity | -68.8% |
Analyst coverage | Low |
Last updated | 24 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2026 | 163 | 21 | 98 | 58 | 4 |
6/30/2025 | 17 | -43 | -63 | -42 | 4 |
6/30/2024 | 3 | -46 | -47 | -46 | 5 |
12/31/2023 | 4 | -41 | -42 | -42 | N/A |
9/30/2023 | 4 | -40 | -39 | -39 | N/A |
6/30/2023 | 4 | -40 | -35 | -35 | N/A |
3/31/2023 | 4 | -38 | -33 | -33 | N/A |
12/31/2022 | 4 | -37 | -30 | -30 | N/A |
9/30/2022 | 5 | -34 | -30 | -30 | N/A |
6/30/2022 | 5 | -32 | -30 | -30 | N/A |
3/31/2022 | 4 | -29 | -25 | -25 | N/A |
12/31/2021 | 4 | -26 | -20 | -20 | N/A |
9/30/2021 | 4 | -28 | -19 | -19 | N/A |
6/30/2021 | 4 | -30 | -18 | -18 | N/A |
3/31/2021 | 5 | -29 | -16 | -16 | N/A |
12/31/2020 | 6 | -27 | -15 | -15 | N/A |
9/30/2020 | 10 | -20 | -13 | -13 | N/A |
6/30/2020 | 14 | -13 | -11 | -11 | N/A |
3/31/2020 | 13 | -15 | -13 | -13 | N/A |
12/31/2019 | 13 | -16 | -14 | -14 | N/A |
9/30/2019 | 9 | -17 | -15 | -15 | N/A |
6/30/2019 | 6 | -18 | -15 | -15 | N/A |
3/31/2019 | 5 | -18 | -13 | -13 | N/A |
12/31/2018 | 5 | -17 | -10 | -10 | N/A |
9/30/2018 | 6 | -15 | -9 | -9 | N/A |
6/30/2018 | 7 | -13 | -8 | -8 | N/A |
3/31/2018 | 6 | -12 | -8 | -8 | N/A |
12/31/2017 | 7 | -10 | -8 | -8 | N/A |
9/30/2017 | 5 | -9 | N/A | -8 | N/A |
6/30/2017 | 4 | -9 | N/A | -9 | N/A |
3/31/2017 | 3 | -10 | N/A | -8 | N/A |
12/31/2016 | 2 | -10 | N/A | -9 | N/A |
9/30/2016 | 2 | -36 | N/A | -10 | N/A |
6/30/2016 | 2 | -62 | N/A | -11 | N/A |
3/31/2016 | 2 | -71 | N/A | -10 | N/A |
12/31/2015 | 1 | -82 | N/A | -8 | N/A |
9/30/2015 | 1 | -57 | N/A | -8 | N/A |
6/30/2015 | 1 | -32 | N/A | -8 | N/A |
3/31/2015 | 1 | -23 | N/A | -10 | N/A |
12/31/2014 | 1 | -14 | N/A | -13 | N/A |
9/30/2014 | 2 | -14 | N/A | -13 | N/A |
6/30/2014 | 2 | -13 | N/A | -14 | N/A |
3/31/2014 | 2 | -13 | N/A | -14 | N/A |
12/31/2013 | 2 | -13 | N/A | -14 | N/A |
9/30/2013 | 2 | -14 | N/A | -15 | N/A |
6/30/2013 | 2 | -15 | N/A | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: YP1A is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: YP1A is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: YP1A is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: YP1A's revenue (71.2% per year) is forecast to grow faster than the German market (5.4% per year).
High Growth Revenue: YP1A's revenue (71.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: YP1A is forecast to be unprofitable in 3 years.